Education Use Only
For educational use only — The physician’s written order and the unit protocol always govern
Medical Associates  ·  Department of Nephrology ← Nursing cards  ·  Maintenance Hemodialysis  ·  urinenephrology.org
Dialysis Nursing Reference Card  ·  Maintenance Hemodialysis

N14 — The Anticoagulated Patient at the Chair

What changes when the patient already takes a blood thinner: heparin, needle sites, bleeding, dose timing, and falls.
Andrew Bland, MD, FACP, FAAP Reviewed September 2026 · v1.0 draft Prints on one sheet, front and back
N14 — The Anticoagulated Patient at the Chair FRONT
Front · at the chair

When: every treatment for a patient on apixaban (Eliquis), warfarin (Coumadin), rivaroxaban (Xarelto), or another blood thinner. The written order and your unit protocol govern.

Do this

  1. Confirm the drug, the dose, and the last dose every treatment (“Did you take your blood thinner last night and this morning?”). Apixaban dose: per your nephrologist’s order / unit protocol.
  2. Heparin: per your nephrologist’s order / unit protocol. Don’t assume the standard bolus and infusion apply; if the order doesn’t address the blood thinner, ask before you start.
  3. If a heparin-free run is ordered, watch for dark streaks in the dialyzer, clot in the venous chamber, or rising venous or transmembrane pressure [3].
  4. Needle sites: firm pressure without stopping flow (you should still feel the thrill). Time it and write down the minutes every session [12].
  5. Warfarin: draw the INR with pre-dialysis labs as ordered. Call when the INR is outside the range in the patient’s order [8].
  6. Ask every week: black or tarry stools, blood in stool or urine, vomiting blood, nosebleeds, new bruising, any fall, any bump to the head [2][9].
  7. Apixaban on dialysis days: usual times — no hold before treatment, no extra dose after [5][6]. Missed dose: the label says take it as soon as possible that day; never double [7].
  8. Before a procedure or catheter change: tell the nephrologist the drug and the last dose. Cannulation needs no hold.
  9. Before the patient leaves: steady, not lightheaded (N5: Intradialytic Hypotension: Chair-Side Response).

Call the nephrologist when

  • Now (and follow your unit emergency plan, N12: Chair-Side Emergencies): a fall with a head strike; new headache, confusion, vomiting, weakness, slurred speech, or vision change; vomiting blood; black or bloody stools; bleeding that won’t stop with firm pressure; a fast-growing access hematoma.
  • Same day: the INR is outside the range in the patient’s order — now if the patient is bleeding.
  • Same day: the circuit clotted on a heparin-free run; blood in the urine; an unexplained hemoglobin drop (N10: Anemia Protocol: ESA and Iron Hold/Report Rules).
  • Same day: new aspirin, clopidogrel, prasugrel, ticagrelor, NSAID, “-azole” antifungal, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort [7]; taking both warfarin and apixaban; a dose that doesn’t match the order; the drug stopped or unaffordable.
  • At rounds: needle-site bleeding longer than the patient’s usual for three sessions in a row [12]; a fall without a head strike.
  • AF patients: see N1: Potassium Bath Selection for potassium call rules.

Don’t

  • Don’t give a heparin bolus to a patient on a blood thinner unless it is ordered.
  • Don’t stop, skip, hold, or double a dose on your own — or tell the patient to [7].
  • Don’t blame all prolonged needle-site bleeding on the drug. Three sessions in a row can mean the access is narrowing (Examining and Cannulating the AVF and AVG).
  • Don’t give vitamin K or a reversal drug without an order.
  • Don’t let a patient leave after a head strike without talking to the nephrologist.
  • Don’t treat a fall as a reason to stop the blood thinner — report it; the physician decides [10].
N14 — The Anticoagulated Patient at the Chair BACK
Back · why, and the evidence

Why

  1. In RENAL-AF, 26–32% of dialysis patients on apixaban or warfarin had a major or clinically relevant bleed within a year, versus about 3% with a stroke or embolism [1]. GI bleeding is the most common major bleed on dialysis (2.3 per 100 patient-years) [2].
  2. In a randomized crossover trial, 10 patients on oral anticoagulants had 40 treatments with and without added circuit anticoagulation; none ended early [3]. The UK Kidney Association suggests a heparin-free start (grade 2D) [4]. The trial predates wide apixaban use — so watch the circuit.
  3. A dialysis session removes about 4% of apixaban, and levels don’t depend on dose timing [5][6]. Dose is debated: the label gives 5 mg twice daily unless age 80 or older or weight 60 kg or less [7]; steady-state data show 2.5 mg twice daily on dialysis matches 5 mg exposure with normal kidneys [5]. Even a 48–72-hour pre-procedure hold may be too short [6].
  4. In RENAL-AF, warfarin patients were in the target INR range only 44% of the time [1], and in a US dialysis cohort, patients whose INR was not checked in the unit had the highest stroke risk [8]. The UK Kidney Association advises reassessing warfarin when time in range falls below 65% [4].
  5. Dialysis patients 65 and older fell 1.6 times per person-year; 19% of falls caused injury [9]. Fall risk alone did not change the best stroke-prevention choice [10], but 1-year mortality after a spontaneous subdural hematoma on dialysis was 45.9% — 81% in those previously on an oral anticoagulant [11].

Go deeper

References

  1. Pokorney SD, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial (RENAL-AF). Circulation. 2022;146:1735-1745. PubMed 36335914
  2. Coyle CR, et al. Major bleeding rates in an international cohort of patients with end-stage kidney disease. Kidney Int Rep. 2024;9:2814-2818. PubMed 39291210
  3. Krummel T, et al. Haemodialysis in patients treated with oral anticoagulant: should we heparinize? Nephrol Dial Transplant. 2014;29:906-913. PubMed 24459138
  4. UK Kidney Association. Clinical practice guideline: anticoagulation for atrial fibrillation in adults with advanced kidney disease. September 2025. ukkidney.org
  5. Mavrakanas TA, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241-2248. PubMed 28302754
  6. Konecki C, et al. Population pharmacokinetic modelling of apixaban in end-stage kidney disease patients with atrial fibrillation receiving haemodialysis. Clin Pharmacokinet. 2025;64:307-321. PubMed 39853633
  7. ELIQUIS (apixaban) prescribing information. Bristol-Myers Squibb; DailyMed label, May 2025. dailymed.nlm.nih.gov
  8. Chan KE, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233. PubMed 19713308
  9. Cook WL, et al. Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol. 2006;1:1197-1204. PubMed 17699348
  10. Man-Son-Hing M, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685. PubMed 10218746
  11. Yang L, et al. Nontraumatic subdural hematoma in patients on hemodialysis with end-stage kidney disease: a systematic review and pooled analysis. Front Neurol. 2023;14:1251652. PubMed 37789893
  12. Lok CE, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. PubMed 32778223

Reviewed by Andrew Bland, MD, FACP, FAAP · v1.0 draft 2026-09-26. For education; the physician’s written order and the unit protocol always govern.